Literature DB >> 34362745

Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study.

Yun Liu1, Zongfei Ji1, Wensu Yu1, Sifan Wu1, Huiyong Chen1, Lili Ma1, Zhenqi Ding1, Lindi Jiang2.   

Abstract

Entities:  

Keywords:  autoimmune diseases; granulomatosis with polyangiitis; systemic vasculitis; treatment

Mesh：

Substances：

Year:  2021        PMID： 34362745     DOI： 10.1136/annrheumdis-2021-220484

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

Review 1.  Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease.

Authors:  Nina Couette; Wael Jarjour; Jonathan E Brammer; Alexa Simon Meara
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

Review 2.  Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.

Authors:  Durga Prasanna Misra; Gaurav Pande; Vikas Agarwal
Journal:  Clin Rheumatol       Date:  2022-10-20       Impact factor: 3.650

Review 3.  B Lineage Cells in ANCA-Associated Vasculitis.

Authors:  Ana Merino-Vico; Jan Piet van Hamburg; Sander W Tas
Journal:  Int J Mol Sci       Date:  2021-12-30       Impact factor: 5.923

Review 4.  Perspectives of JAK Inhibitors for Large Vessel Vasculitis.

Authors:  Ryu Watanabe; Motomu Hashimoto
Journal:  Front Immunol       Date:  2022-03-30       Impact factor: 7.561

5.  Extended-release tofacitinib for refractory Behçet disease: A case report.

Authors:  Chrong-Reen Wang; Tak-Wah Wong; Sheng-Min Hsu
Journal:  Medicine (Baltimore)       Date:  2022-04-15       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.